George Steuart Health recently announced the launch of ‘Cilacar’, a revolutionary discovery of an advanced Calcium Channel Blocker, for the first time in Sri Lanka. Cilacar was introduced during a medical symposium hosted by the George Steuart Health in collaboration with Unique Pharmaceuticals, India. The event was held at the Waters Edge – Battaramulla, where many dignitaries representing local and international medical fraternity including Senior Cardiologists, Nephrologists and Neurologists graced the occasion. The symposium featured Guest Speakers from India: Dr. Rajiv Karnik (Director – Heart Failure Clinic and Interventional Cardiologist at Fortis Hospital, Mumbai) and Dr. Sharad Sheth (Senior Consultant Nephrologist), in addition to a Presentation of the newly launched drug. A panel discussion was also held with the participation of prominent medical luminaries: Dr. Chula Herath (Consultant Nephrologist and President – Sri Lanka College of Nephrologists), Dr. Priyankara Jayawardena (Consultant Physician) and Dr. Mubarak (Consultant Cardiologist and Immediate Past President – Sri Lanka Heart Association). Cilacar – Cilnidipine was launched under the patronage of Mr. Dilith Jayaweera (Chairman – George Steuart Group of Companies), Mr. P.K. Singh (President Global Business – Unique Pharmaceuticals, India) and Mr. Eran Ranasinghe (Executive Director – George Steuart Health). It was also significant that the new drug was launched harnessing 3D hologram technology, for the first time in Sri Lankan pharmaceutical industry. Addressing the symposium, Mr. Eran Ranasinghe – Executive Director of George Steaurt Health noted, “Introducing a new molecule is a herculean task. And we have toiled for almost 6 years to obtain the necessary approvals for this new chemical entity. We are thankful to the authorities and the eminent evaluation sub-committee members for approving this molecule, which will be beneficial to the Sri Lankans at large. Today, we are proud to present to you Cilacar – Cilnidipine in strengths of 5mg and 10mg, which will be a boon, especially to the hypertensives with renal impairment.” Commenting his views at the occasion, Dr. Sharad Sheth (Nephrologist) noted, “Hypertension substantially increases the risk of kidney diseases and vascular complications. Arterial hypertension together with proteinuria is one of the most important factors associated with the progression of both diabetic and non-diabetic chronic kidney disease. Therefore, I believe Cilacar – Cilnidipine will play a pivotal role in combating non-communicable diseases, such as cardio-vascular and kidney diseases, in addition to effectively treating high blood pressure.” In his presentation, Dr. Rajiv Karnik presented a comparison of calcium channel blockers versus other anti-hypertensives. He also highlighted the benefits offered by 4th generation Calcium channel blockers in control of hypertension over older generations, with evidence from clinical trials. George Steuart Health, is the leading subsidiary of Sri Lanka’s oldest mercantile establishment and diversified conglomerate: George Steuart & Company. Being a company in the forefront of Sri Lanka’s premier healthcare and wellness solution providers, George Steuart Health is partnered with over 60 international principals and markets more than 1400 Stock Keeping Units. 
adaderana business